Biophysical Detection of Diversity and Bias in GPCR Function

Fluorescence resonance energy transfer/time-resolved FRET

A number of FRET-based techniques exist and have been extensively reviewed elsewhere (32). Intensity-based FRET methods have their limitations due to the overlap of fluorophore excitation and emission spectra (33). Bleedthrough of the donor emission into the acceptor detection window needs to be removed, as does the component of the acceptor emission resulting from direct acceptor excitation. Spectral unmixing is one approach to address this issue (34).

Alternatively, the “unmixing” can occur temporally through the utilization of time-resolved FRET (TR-FRET), which can also overcome issues of photobleaching and high background autofluorescence (35). This approach relies on energy transfer between lanthanide donors (such as europium or terbium cryptate complexes) and a suitable acceptor (such as the Cy-5-like cyanine dye, d2, or the modified allophycocyanine, XL665). The exceptional duration of fluorescence emission (300–1000 μs) from lanthanide donors enables measurement of acceptor emission long after background fluorescence has decayed (35). This, together with the high FRET efficiency between lanthanide and cyanine fluorophores, and the chemically stable nature of cryptate complexes, results in excellent signal-to-noise ratios for TR-FRET. As such, TR-FRET assays are well suited to high-throughput screening (36), as well as general investigative studies. When combined with labeling methods such as SNAP- and CLIP-tag technology or fluorescent ligands, TR-FRET becomes a powerful tool for detecting GPCR proximity. For example, a recent paper from the Milligan laboratory investigated cannabinoid receptor 1 (CB₁) and orexin receptor 1 (OX₁) heteromerization using TR-FRET and SNAP/CLIP tags, providing evidence for a remarkable ability of OX₁ to induce internalization of the CB₁–OX₁ heteromer with greater potency than observed with OX₁ alone (37). Similar approaches have been used to determine the stoichiometry of homo- and heteromer populations at the cell surface, specifically within the metabotropic glutamate (mGlu) receptor family (38) or between dopamine D2 and D3 receptors (39).

Fluorescent ligands (see section below) offer a powerful alternative approach to labeling GPCR complexes (40–42), by removing the requirement for engineered fusion proteins. Consequently, they enable investigation of GPCR complexes in their native environment, which is particularly useful given that the existence of heteromers in vivo is much less well-established than in vitro. Notably, TR-FRET between fluorophore-conjugated antagonists has been used to demonstrate the existence of oxytocin receptor homomers in primary mammary tissue (43, 44).

A recent paper demonstrated the use of TR-FRET antibodies to quantify levels of EGFR/HER2 heterodimerization since simultaneous in vivo treatment with antibodies that disrupted this complex resulted in the greatest median survival rate (45). Such a technique could also be used for screening compounds that regulate heteromerization of GPCR complexes, depending upon the availability of suitably validated GPCR antibodies and a distinct and measurable functional effect of a particular complex. The presence and proximity of protomers that constitute a GPCR complex may also be inferred using epitope-tagged receptors and fluorescently labeled antibodies to these epitopes. For example, to detect proximity between CXCR3 and CXCR4, these receptors were N-terminally epitope-labeled (HA-CXCR3/FLAG-CXCR4) and TR-FRET was measured between TR-FRET-labeled antibodies to these epitopes (46).

Bioluminescence resonance energy transfer

Following the oxidation of a suitable substrate by a luciferase enzyme, typically a variant of Renilla luciferase (Rluc), such as Rluc2 or Rluc8, BRET occurs through a non-radiative transfer of energy to a complementary fluorophore, such as a variant of GFP, if it is in sufficiently close proximity (47, 48). Critically, as with FRET, energy transfer is dependent upon the distance between donor and acceptor (inversely proportional to the sixth power), as well as their relative orientation and degree of spectral overlap (29, 30, 49). The BRET process occurs naturally in marine organisms such as the jellyfish Aequorea victoria and sea pansy Renilla reniformis. Since the seminal use of this technique to observe interacting clock proteins (50), BRET has been used increasingly to monitor proximity indicative of association, dissociation, or conformational changes involving proteins of interest (29). Indeed, this method can be used to observe intramolecular changes to protein conformation in a bimodal manner indicating active or inactive states. This is particularly important for biosensors, and will be detailed in the next section (see Resonance Energy Transfer Biosensors).

Recent innovations in BRET technology have been extensively reviewed (30), but briefly, the original BRET approach (now termed BRET¹) generally uses an Rluc variant and yellow fluorescent protein (YFP), as the donor and acceptor respectively, with coelenterazine h as the enzyme substrate. A second generation, termed BRET², uses a synthetic coelenterazine, DeepBlueC, with a blue-shifted donor emission spectrum, and modified GFP (GFP²) (51). GFP10 is also a suitable BRET² acceptor (52–55). BRET² has the advantage of increased spectral resolution between donor and emission peaks, but this is overshadowed by rapid decay kinetics of the substrate and a substantially reduced quantum yield (56, 57). The distance ranges over which BRET¹ and BRET² energy transfer occurs are comparable with FRET, with BRET¹ being more sensitive to proximity than BRET² (58). BRET¹ with Rluc/enhanced YFP, and BRET¹ with Rluc2 or Rluc8/Venus, exhibit minimal energy transfer beyond about 6.5 and 8 nm, respectively, whereas BRET² extends to about 11 nm regardless of whether Rluc, Rluc2, or Rluc8 is used (58).

Another permutation of BRET known as “extended BRET” (eBRET) utilizes a protected variant of coelenterazine h (EnduRen) and enables real-time monitoring of interactions for extended time periods (47, 59, 60). This enables discrimination of distinct kinetic profiles, such as between mutated receptors (61, 62). Similarly, protected DeepBlueC variants have also been produced, and may be of use to take advantage of increased spectral resolution with a lengthened substrate half-life (63). A further modification known as BRET³, utilizing a mutant fluorescent protein with red-shifted emission (mOrange), has also proved useful for in vivo imaging (64, 65). Other variations of BRET, including multiplexing, have also been devised to allow multiple acceptor fluorophores, conjugated to various proteins of interest, to be activated in a cascade manner (66). For example, this has been used to detect proximity between three proteins in a GPCR complex (67).

Recently, an investigation was carried out into novel luciferases from marine organisms that resulted in the isolation and optimization of a novel luciferase, “NanoLuc™,” derived from the deep sea shrimp Oplophorus gracilirostris (28). Concurrently, a novel imidazopyrazinone substrate, furimazine, was specifically developed for use with this novel enzyme. NanoLuc™ is almost half the size of Renilla luciferase [19 versus 36 kDa, respectively (28)], and this could potentially result in a lower degree of interference or steric hindrance of the luciferase tag when fused to a protein of interest in mammalian cells. NanoBRET™ benefits from the substantially increased brightness of NanoLuc™(28), enabling very low levels of enzyme expression to be used. Furthermore, the 460-nm emission maximum of NanoLuc™(28) is blue-shifted compared to the Rluc variants with emission peaks of about 480 nm (57). Along with the approximately 20% narrower spectral emission of NanoLuc™(28), this enables better spectral separation from the acceptor emission.

Resonance energy transfer biosensors

Biosensors are novel molecular tools that can be used to investigate the activity of a signaling or structural protein qualitatively and/or quantitatively (68, 69). This may be in the form of bimodal output, whereby either unimolecular or bimolecular peptide probes are synthesized to include certain domains that measure a change in the inactive or active state of an effector protein, and this consequently causes a change in conformation of the biosensor, and magnitude of signal output (68, 69). Importantly, these can be used as screening tools to measure the activity of signaling or structural protein activity in a high-throughput situation. Several FRET biosensors have been developed for small GTPases, involved in a number of regulatory and signaling activities in the cell (68). Intracellular Ras activity of angiotensin receptor type 1 (AT₁R) stimulated by angiotensin II has been observed using a Ras biosensor, and found to have activity in certain compartments (70). GTPases are activated and deactivated by guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs), respectively (71). Therefore, if these proteins are known, and the domains that they affect, fusion proteins can be developed involving either a single domain, or two domains. If the effector causes a considerable change in conformation, this may be sufficient to enable a difference in the RET signal to be detected. This has been developed for Rab5, a member of the Rab family of GTPases involved in trafficking of GPCRs and other proteins in transport vesicles throughout various compartments in the cell (71), Quantitative changes using FRET probes have typically been used as the RET method for a large proportion of characterized biosensors, however, BRET probes are increasingly being used. An ERK sensor “REV” has been developed incorporating BRET tags to measure the phosphorylated or unphosphorylated state of ERK (72). Similarly, G protein activation can be inferred by monitoring interactions between G proteins and GPCRs using BRET (53, 73–75). Other examples include BRET biosensors for cAMP (76) and protein kinase A (77) [see Ref. (78) for review]. Although biosensors can be created using artificial constructs, native proteins may also be tagged at either N- or C-termini, or by integrating FRET or BRET tags into internal domains of the protein, such as the third intracellular loop of GPCRs, as recently demonstrated for an odorant GPCR (79). Additionally, homogeneous time-resolved fluorescence (HTRF) is a biosensor platform with a range of applications (80), including measurement of inositol-1-phosphate (61, 81, 82) and cAMP (61). Due to the impermeability of the metal chelates, HTRF measurement either requires cell lysis or mild cell permeabilization, the latter with Triton X-100 for example (75).

Proximity between BRET-tagged β-arrestin and BRET-tagged ubiquitin can be monitored following activation of a co-expressed GPCR, and the resultant kinetic profiles provide interesting insights into receptor pharmacology, as seen when comparing V₂R with β₂ adrenoceptor (83) or different orexin receptor subtypes (62, 84). Alternatively, BRET¹ and BRET² can be utilized in parallel by co-expressing Rluc-tagged β-arrestin, YFP-tagged GPCR, and GFP²-tagged ubiquitin, then measuring BRET in parallel cell populations following addition of coelenterazine h (BRET¹) or DeepBlueC (BRET²) substrate (83).

Detection and profiling of GPCR heteromer complexes

The agreed definition of a receptor heteromer is a “macromolecular complex composed of at least two (functional) receptor units with biochemical properties that are demonstrably different from those of its individual components” (85). Notably, heteromeric complexes may exist without GPCRs interacting directly, as other complex components may be in between (86). To detect specific heteromer complexes of GPCRs, suitable experimental controls are required to differentiate between specific and non-specific (bystander) reporter signals.

The Receptor-Heteromer Investigation Technology (Receptor-HIT) (87), includes Receptor Tyrosine Kinase-HIT (RTK-HIT) (88) and the GPCR-Heteromer Identification Technology (GPCR-HIT) as a novel approach for rapid identification, screening, and profiling of GPCR heteromers (30, 46, 86, 87, 89–92) (Figure 1). The approach consists of three essential components co-expressed in live cells, (i) a GPCR fused to a proximity-based first reporter component, (ii) an unlabeled GPCR, and (iii) a GPCR-interacting group, linked to the complementary second reporter component, whose interaction with the complex is modulated upon binding a ligand selective for the unlabeled GPCR or the heteromer complex specifically. Typically the first reporter component is fused to the C-terminus of the GPCR and an intracellular interacting group is used (Figure 1A), such as β-arrestin (86) or tagged G protein subunits (75). Indeed, our work with EGFR–HER3 complexes recruiting Grb2 illustrates the diversity of potential intracellular receptor interacting partners (88). However, by fusing the first reporter component to the N-terminus of a GPCR and using a fluorescently labeled ligand as the interacting group/second reporter component combination (Figure 1B), GPCR-HIT can be used to assess ligand binding to the heteromer. Upon expression of the aforementioned three components in cells, a ligand specific for the unlabeled GPCR or the heteromer complex is added and the reporter signal measured. If the GPCRs are not proximal, addition of the ligand specific to the untagged GPCR will modulate the interacting group’s proximity to the activated receptor, however, as the two reporter components will not be in close proximity, no modulation of the reporter signal will be measured. In contrast, when heteromers of the GPCRs are present, addition of ligand will modulate the interacting group’s proximity to the complex, resulting in a change in reporter signal (Figure 1).

GPCR-HIT can be used on a broad range of reporter assay platforms including FRET (e.g., CisBio’s HTRF^®), BRET, bimolecular fluorescence complementation (BiFC), bimolecular luminescence complementation (BiLC), enzyme fragment complementation (e.g., DiscoveRx’s PathHunter^®), and proteolysis-based reporter systems (e.g., Invitrogen’s Tango™). The GPCR-HIT technique was recently demonstrated for two well characterized heteromers, CCR2–CXCR4 and CCR2–CCR5 (86). In this study, untagged CCR2 was co-expressed with β-arrestin2/Venus YFP and Rluc8-tagged CXCR4 or CCR5. Addition of CCL2, the ligand selective for CCR2, caused an increase in BRET signal indicative of β-arrestin recruitment to the heteromeric complex (86). In addition to dose–response and kinetic profiles, Z′ factors were determined (>0.6) for β-arrestin recruitment, which demonstrate the suitability of this assay for drug screening programs (86).

GPCR-Heteromer Identification Technology was used to identify and profile a novel α_1AAR–CXCR2 heteromer, potentially relevant to benign prostate hyperplasia (BPH) (92). The α_1AAR is an important mediator of prostatic smooth muscle tone and lower urinary tract function. Consequently, α_1AAR antagonists are used in the treatment of BPH (93). Typically, α_1AAR interacts extremely weakly, if at all, with β-arrestin in HEK293 cells (94). However, α_1AAR coimmunoprecipitates with β-arrestin in prostate smooth muscle cells (95), suggesting a necessary cofactor may be missing in HEK293 cells. We employed GPCR-HIT in HEK293 cells using BRET with β-arrestin2/Venus as the acceptor. When α_1AAR/Rluc8 was expressed alone, norepinephrine failed to induce recruitment of β-arrestin2/Venus to the receptor. However, when CXCR2 was co-expressed, norepinephrine caused a marked increase in BRET signal, suggestive of a heteromeric complex. Further investigation using CXCR2/Rluc8 and untagged α_1AAR with β-arrestin2/Venus revealed a much larger increase in BRET signal compared to the reverse (BRET tag) configuration, indicating that β-arrestin2 may be recruited to CXCR2 via an allosteric interaction with norepinephrine-activated α_1AAR. Interestingly, the norepinephrine-dependent β-arrestin recruitment was inhibited by SB265610, a CXCR2-specific inverse agonist, in addition to Terazosin, an α_1AAR antagonist. Furthermore, BRET studies with both receptors tagged suggest that α_1AAR–CXCR2 heteromerization is constitutive and not ligand-dependent (92).

Critically, the increase in signal observed with GPCR-HIT is ligand-dependent and specific to the heteromeric complex. The latter attribute is particularly important for demonstrating unique pharmacology arising from heteromerization, whilst the former enables heteromer-specific or biased compound screening and profiling (89, 91). BRET saturation and competition assays are often used to demonstrate the specificity of an interaction, however, they do not provide important functional information, as demonstrated when BRET saturation experiments were used to assess the α_1AAR–CXCR2 heteromer using α_1AAR and vasopressin receptor 2 (V₂R) as a control (92). Surprisingly, co-expression of α_1AAR and V₂R also resulted in a hyperbolic curve indicative of specific proximity, despite a distinct lack of noticeable change in receptor pharmacology and an absence of norepinephrine-induced β-arrestin recruitment. In contrast, norepinephrine caused a marked increase in β-arrestin recruitment to the α_1AAR–CXCR2 heteromer when compared to α_1AAR alone (92). BRET competition assay data, where increasing expression of an unlabeled receptor reduces the BRET signal between BRET-tagged receptors, should also be interpreted with caution. This is because increasing the expression of unlabeled receptor can result in lower expression of the BRET-tagged receptors, artifactually resulting in a lower BRET signal (29). Therefore, whenever such competition data are presented, they should be supported by data showing relative receptor expression levels in the presence and absence of the competitor.

Protein-fragment complementation assay

Protein-fragment complementation assay (PCA) represents another useful method for examining protein–protein interactions both in vitro and in vivo (96, 97). With this approach, each protein of interest is fused to one component of a split reporter protein (Figure 2). In the absence of any interaction, the separate fragments remain inactive (Figure 2A), however, when the two proteins of interest interact in an appropriate manner, the complementary fragments recombine to form a functional reporter protein (Figure 2B). Various reporters can be used including β-lactamase, dihydrofolate reductase, tobacco etch virus (TEV) protease, GFP variants (termed BiFC), and luciferase (termed bimolecular luminescence complementation, BiLC) (98, 99). Each has particular advantages and limitations depending on the application. For example, BiFC can be combined with fluorescence microscopy to investigate the intracellular localization of the interacting proteins. However, the recombination of GFP variants is irreversible, and interactions cannot be visualized in real time due to the slow maturation of the GFP. In contrast, luciferase-based PCA fragments appear to mature faster and are thought to be more reversible (97, 100). On the other hand, luminescence-based assays are generally not suitable for high resolution imaging. PCA is particularly useful for detecting weak protein–protein interactions and can provide some measure of affinity, as for weak interactions, BiFC signals are believed to be proportional to interaction strength (101). However, careful selection of experimental controls is also required (99), as by necessity the two reporter fragments must retain some affinity for one another. Nevertheless, when combined with other approaches, PCA is clearly a powerful technique. For example, BiFC and GPCR-HIT were recently used in parallel to investigate the novel pharmacology of AT₁–AT₂ heteromers (90).

Combinations of PCA and RET approaches

Protein-fragment complementation assay can also be combined with BRET or FRET to examine complexes containing three or more proteins. For example a combination of BRET and BiFC, using Rluc-tagged adenosine A_2A receptors (A_2AR), along with A_2AR-N-YFP and A_2AR-C-YFP, was used to detect higher-order oligomeric complexes of A_2AR (102). Similarly, BRET experiments have been carried out with dopamine D₁ and D₂ receptors tagged with split Rluc8 fragments as well as Venus-tagged Gα subunits, to demonstrate functional selectivity arising from heteromerization (103). Furthermore, by using four fragments (split Rluc and split Venus), Guo et al. demonstrated that the dopamine D₂ receptor (D₂R) can exist in a complex of at least four receptor protomers (104). BRET has also been combined with FRET to give sequential RET (SRET) (105). Combinations of three fusion proteins were used, Rluc-, YFP-, and DsRed-tagged (SRET¹) or Rluc-, GFP²-, and YFP-tagged (SRET²) (105). If all three proteins are present in a complex, then Rluc substrate oxidation enables energy transfer from Rluc to the BRET acceptor (e.g., YFP), which then has the potential to act as a FRET donor to give sequential energy transfer to the FRET acceptor (e.g., DsRed). Complex formation is then inferred by specific measurement of FRET acceptor emission. This approach was recently used to provide evidence for heteromerization of adenosine A_2A, dopamine D₂, and cannabinoid CB₁ receptors (105). Similarly, SRET was used to investigate higher-order complexes of adenosine A_2A, D₂, and mGlu₅ receptors (106).

Proximity ligation assay

Proximity ligation assay (PLA) is a highly sensitive technique used to directly visualize protein–protein interactions with single-molecule resolution (107). PLA is an antibody-based approach of which several variations exist [see Ref. (108) for review]. In one of the more commonly used formats, two proteins of interest are targeted with primary antibodies from different species, and further labeled with two specific secondary antibodies conjugated to oligonucleotides. Complementary oligonucleotides are added to enable proximity-dependent (<40 nm) hybridization and ligation to form a circular DNA template. The template is then amplified in situ and visualized with a fluorescently labeled oligonucleotide probe. This approach yields a number of advantages over well-established imaging techniques in that the amplification step enables the visualization of individual protein complexes, whilst the in situ nature of the assay allows for determination of subcellular localization. Furthermore, as bioengineered protein constructs are not required, PLA can be used to visualize protein–protein interactions in primary tissue. Notably, PLA was used in a recent study in the Javitch laboratory to identify dopamine D₂ and adenosine A_2A receptor heteromers in the striatum of mice ex vivo (109). An important caveat is that PLA requires the use of well-validated antibodies, which are not always available for GPCRs. Nevertheless, PLA remains a powerful technique for investigating GPCR heteromers, as exemplified by studies on dopamine D₂–D₄ receptor heteromers in HEK293T cells (110) and cysteinyl leukotriene receptor-1 and -2 heteromers in INT-407 intestinal epithelial cells (111).

Fluorescence correlation spectroscopy and the measurement of ligand-binding in single cells, membrane microdomains, and nanodiscs

Biased signaling to particular intracellular signaling pathways (113, 128–130) can be considered to be equivalent to the regulation of GPCR ligand-binding and efficacy caused by small allosteric ligands. In this case, however, it is the binding of intracellular signaling proteins to the intracellular facing domains of the GPCR that mediates the allosteric effect. It is well-established that allosteric ligands bind to a site distinct from the orthosteric binding site occupied by the endogenous natural ligand and produce conformational changes in the receptor that may alter orthosteric ligand-binding affinity, agonist efficacy, or both (113, 131–133). In a similar manner, the interaction of a signaling protein with a receptor has the potential to change the binding affinity of the orthosteric ligand as a consequence of this allosteric interaction. A feature of allosterism is that the effects observed are probe-dependent (113, 132, 133). This means that the consequence of any allosteric influence on the receptor will depend on the ligand (probe) occupying the orthosteric site. As a consequence, agonists will usually have a higher affinity for the receptor when it is bound to an intracellular signaling protein and this will depend on both the orthosteric agonist involved and the signaling protein to which the receptor is coupled. This can manifest as signaling bias.

The location of the receptor and the signaling proteins can also have a major impact on the signaling outcome of receptor activation. It is now known that GPCRs and signaling proteins can be compartmentalized within the cell membrane (134–137). It is also clear that signaling from GPCRs can be mediated from intracellular domains following their internalization (138–141). This not only provides a mechanism by which intracellular signaling can be orchestrated by location within a cell, but also points to the potential for different signaling pathways to be activated by the same receptor in different cellular or membrane locations (135–137). The latter possibility raises the need to develop techniques by which the pharmacology of a receptor in a specific domain or location can be monitored. One such technique is fluorescence correlation spectroscopy (FCS) (142).

Fluorescence correlation spectroscopy is a quantitative biophysical technique that can measure the diffusional characteristics and estimate the number of fluorescent particles (e.g., GPCR complexes, signaling proteins, or fluorescent ligand-occupied receptor complexes) within highly localized membrane microdomains of single living cells (~0.2 μm²) (142–146). Fluorescent ligands in combination with FCS have also been used to study the properties and behavior of a number of different GPCRs in discrete membrane microdomains of single cells (117, 120, 134).

Fluorescence correlation spectroscopy uses a small confocal detection volume created by focusing a laser to a diffraction-limited spot using a lens with a high numerical aperture [see Ref. (142) for further details]. Essentially, the resulting detection volume is approximately 0.25–0.5 fl depending on the particular excitation wavelength being used (i.e., a larger volume is created with a red 633 nm laser compared to a green 488 nm laser). As fluorescent molecules (free fluorescent ligands, receptor-bound fluorescent ligands, GFP-tagged receptor complexes) diffuse through this volume, they are excited by the laser and the emitted photons are detected in a time-correlated manner using a single-photon counting device (e.g., an avalanche photodiode). Over a period of time, this leads to fluctuations in the measured mean level of fluorescence intensity. Autocorrelation analysis (142) of these fluctuations provides information on how long the species responsible for a particular fluorescent fluctuation is present within the confocal volume (the average dwell time, t_D) and also the number (N) of diffusing fluorescent species present. As the fluorescent fluctuation data are collected in a time-correlated manner, it is possible to extract from this information the number of fluorescent particles present with particular t_D values in complex mixtures (142).

In the context of ligand-binding experiments, it is therefore possible to obtain from FCS experiments the concentrations (deduced from N and the actual confocal volume) of both fluorescent ligand and ligand–receptor complexes on the basis of their differing diffusion coefficients (117, 120, 134, 142). For example, previous FCS work with a fluorescent adenosine A₃ receptor (A₃R) agonist in CHO cells expressing the human A₃R revealed an agonist-occupied A₃R complex with a membrane diffusion coefficient of 0.12 μ²m/s (134). It is worth pointing out that this is too slow to represent a single receptor and is more likely to be representative of an oligomeric signaling complex within which the receptor resides (117). Competition studies with an A₃R-antagonist (MRS1220) and an A₃R-agonist (NECA) indicated that this component had high affinity (low nanomoles) for both agonists and antagonists (134). These data suggest that, at the very low concentrations of fluorescent A₃R-agonist required for FCS, selective labeling of the active (R*) form of the A₃R can be achieved (134). Furthermore, the lack of effect of pertussis toxin on this high-affinity agonist binding suggested that the agonist-occupied receptor detected was not coupled to G_i proteins (134).

The ability of FCS to effectively work at high resolution in single-photon detection mode means that it also has the potential to monitor ligand-binding events to solubilized and purified GPCRs. The most successful approach to the reconstitution of these purified GPCRs into a membrane environment has come from the use of high-density lipoproteins (HDLs). HDLs, which are composed of a dimer of apolipoprotein A–I surrounding a planar bilayer of approximately 160 phospholipids, can be reconstituted in vitro to produce a disk-shaped structure (nanodisc or nanolipoprotein particle) of 10–12 nm in diameter and a thickness of 40 Å (147). Recently, nanodiscs have been used to solubilize the Neurokinin 1 receptor (NK1R) and to investigate the kinetics of the binding of fluorescent substance P to substance P-bound NK1R contained within nanodiscs (148). The combination of these techniques has the potential to investigate ligand-binding to defined receptor–receptor and receptor–signaling protein stoichiometries (149).